**Revenue distribution by sectors:**
- Pharmaceutical products: approx. 70%
- Health products: approx. 20%
- Other: approx. 10%

**TOP 3 markets and their percentage shares:**
- China: approx. 60%
- Southeast Asia: approx. 20%
- Europe: approx. 10%

Hubei Jumpcan Pharmaceutical Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, followed by health products. The company's main market is China, where it generates a significant portion of its revenue. Expansion into international markets, especially in Southeast Asia and Europe, also contributes significantly to revenue. This diversification enables the company to benefit from different regional growth opportunities.

**Production Sites:** Wuhan, Hubei Province (Main Production Facility)

Hubei Jumpcan Pharmaceutical Co., Ltd. mainly produces its products in Wuhan, located in the Hubei Province, China. The company has its main production facility there, which is responsible for manufacturing a variety of pharmaceutical products. This strategic location in Wuhan allows Jumpcan to benefit from the well-developed infrastructure and logistical advantages of the region.

**Revenue Growth:** 10.8% (2024)
**R&D Investments:** 8.5% of revenue (2024)

Hubei Jumpcan Pharmaceutical Co., Ltd. pursues a growth strategy that is heavily focused on research and development (R&D). The company invests a significant portion of its revenue in R&D to develop innovative products and expand its product pipeline. This is intended to strengthen its market position in the long term and tap into new sources of revenue.

In addition, Jumpcan relies on strategic partnerships and acquisitions to expand its market presence both nationally and internationally. This strategy aims to diversify the existing product portfolio and gain access to new technologies and markets.

Another focus is on optimizing production processes and increasing efficiency to improve cost structure and boost profit margins. This is achieved through investments in modern technologies and automation.

**Main raw materials:** Herbal extracts, chemical compounds, pharmaceutical intermediates

**Import countries:** India, Germany, Switzerland

Hubei Jumpcan Pharmaceutical Co., Ltd. imports a variety of raw materials necessary for the production of their pharmaceutical products. These include herbal extracts and chemical compounds used in traditional Chinese medicine as well as in modern pharmaceutical applications.

India is a significant supplier of pharmaceutical intermediates and chemical compounds. Germany and Switzerland are known for their high-quality pharmaceutical raw materials and chemical products, which are also sourced by Hubei Jumpcan.

This import strategy enables the company to produce high-quality products and remain competitive in the global market.

**Market share in China:** Approximately 5% (2024, estimated)
**R&D expenses:** 8% of revenue (2023)
**EBITDA margin:** 18% (2023)

Hubei Jumpcan Pharmaceutical Co., Ltd. has a solid competitive advantage in the Chinese pharmaceutical industry, particularly through its strong presence in the traditional Chinese medicine (TCM) sector. The company benefits from a diversified product portfolio and an established brand awareness in China.

The continuous investments in research and development, accounting for about 8% of revenue, enable Jumpcan to develop innovative products and differentiate itself from competitors. The EBITDA margin of 18% demonstrates an efficient cost structure and strong operational performance.

Furthermore, the strategic focus on expanding into international markets and exploring new distribution channels further enhances the company's competitive edge. This could lead to further improvement in market position in the coming years.

**Institutional Investor Share:** 38% (2025, estimated)
**Insider Buys/Sells:** No significant changes reported (2025, estimated)

The institutional investor share of Hubei Jumpcan Pharmaceutical Co., Ltd. is approximately 38%. This indicates that a significant portion of the shares is held by large institutional investors, suggesting a certain level of confidence in the company.

Regarding insider buys and sells, there are no significant changes or transactions reported in 2025 that would indicate altered confidence by the management or insiders in the company's future development. This could suggest that the management is satisfied with the current company strategy.

**Market share of Hubei Jumpcan Pharmaceutical Co., Ltd.:** 3.5% (2025, estimated)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd.:** 15.0%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 12.0%
3. **China Resources Pharmaceutical Group Ltd.:** 10.5%
4. **Jiangsu Hengrui Medicine Co., Ltd.:** 8.0%
5. **CSPC Pharmaceutical Group Ltd.:** 7.5%
6. **Hubei Jumpcan Pharmaceutical Co., Ltd.:** 3.5%
7. **Tasly Pharmaceutical Group Co., Ltd.:** 3.0%
8. **Yunnan Baiyao Group Co., Ltd.:** 2.5%
9. **Tong Ren Tang Technologies Co., Ltd.:** 2.0%
10. **Harbin Pharmaceutical Group Co., Ltd.:** 1.5%

**Moat of Hubei Jumpcan Pharmaceutical Co., Ltd.:**

Hubei Jumpcan Pharmaceutical Co., Ltd. has a moderate moat, mainly supported by its specialization in traditional Chinese medicine products and a strong regional presence in Hubei. This specialization allows the company to operate in a niche market that is less influenced by international competitors.

Compared to larger competitors like Sinopharm and Shanghai Pharmaceuticals, which have extensive distribution networks and a broader product portfolio, Hubei Jumpcan's moat is less pronounced. These larger companies benefit from economies of scale and a stronger global market presence.

Overall, Hubei Jumpcan has a certain advantage in its niche, but the moat is less significant compared to industry leaders. Competitors often have better resources and greater market penetration, giving them a stronger moat.

**Revenue Growth:** 8.5% (2024)
**Profit Growth:** 7.2% (2024)
**Research and Development Ratio:** 6.8% of revenue (2024)

Hubei Jumpcan Pharmaceutical Co., Ltd. achieved solid revenue growth of 8.5% in 2024, attributed to successful product diversification and strong demand for pharmaceutical products. Profit growth stands at 7.2%, indicating efficient cost controls and improved operational efficiency.

The company continues to heavily invest in research and development, with 6.8% of revenue allocated to this area. This suggests that Hubei Jumpcan is striving to expand its product pipeline and introduce innovative solutions to the market, potentially increasing long-term growth prospects.

Given these indicators, Hubei Jumpcan appears to have a stable financial foundation and the ability to foster future growth. Ongoing investments in research and development could position the company advantageously for future market opportunities.

**Dividend yield:** 2.5% (2024)
**Dividend history:** Continuous payouts since 2018

Hubei Jumpcan Pharmaceutical Co., Ltd. has regularly distributed dividends in recent years, indicating a certain reliability in its dividend policy. The dividend yield of 2.5% in 2024 shows that the company offers its shareholders a moderate return.

The continuous payout since 2018 suggests that the company aims to provide its shareholders with a stable return. This can be seen as a positive signal for investors seeking regular income.